arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Nkarta, Inc.

NKTX
$2.75 ▼ -0.20 (-6.78%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
19 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nkarta, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $204.9M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -13.8% ↘
FCF / Share $-0.33 ↗
Trailing P/E —
Price / Book 0.8x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↑ +100.0% —
Net Income Profit after all expenses
$-27.83M
↑ +13.0% —
FCF / Share Free cash flow per share
$-0.33
↓ -28.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns →
22
Cash Quality →
58

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters